Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies
ConclusionsThis study could help identify patients with ErbB2-positive tumors that are at increased risk of disease relapse following NATs.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neoadjuvant Therapy | Study | Women